Summary.-Mammary tumours were induced in 3 groups of male Long-Evans rats by a series of 6 fortnightly gastric intubations of 7, 12-dimethylbenzanthracene. Two weeks before the initial carcinogen treatment one group of rats was grafted with 3 pituitary homografts underneath the kidney capsule of each recipient (hyperprolactinaemia). A second group, 2 weeks before the initial carcinogen treatment and for the duration of the study (35 weeks), were injected 4x weekly with 2-Br-oaergocryptine (CB-154) (hypoprolactinaemia). A third group of rats served as controls. A significant increase in the incidence of mammary tumours and a reduced latency period of tumour appearance in the hyperprolactinaemia group, when compared with the controls, were observed in this study. Mammary tumour incidence and latency period of tumour appearance in the hypoprolactinaemia group, however, did not differ significantly from controls. Thus, an increased secretion of pituitary prolactin in rats appears to be an important enhancing endocrinic condition in carcinogenesis of the male mammary gland.
ergocryptine (CB-154) (hypoprolactinaemia). A third group of rats served as controls. A significant increase in the incidence of mammary tumours and a reduced latency period of tumour appearance in the hyperprolactinaemia group, when compared with the controls, were observed in this study. Mammary tumour incidence and latency period of tumour appearance in the hypoprolactinaemia group, however, did not differ significantly from controls. Thus, an increased secretion of pituitary prolactin in rats appears to be an important enhancing endocrinic condition in carcinogenesis of the male mammary gland.
THE ADMINISTRATION of 7, 12-dimethylbenzanthracene (DMBA) has been a standard procedure for over a decade for the rapid production of mammary carcinomata in laboratory rats (Huggins, 1965) , an experimental model which in certain respects resembles human breast cancer (Dao, 1964; Middleton, 1965) . In the female rat, this procedure results in mammary carcinomata of high yield that are hormone responsive. The hormonal dependency of these carcinomata has been studied intensely and it appears that the major influential hormones in this process are oestrogen and prolactin (Daniel and Prichard, 1964; Welsch, Clemens and Meites, 1969) . Growth hormone (Young, 1961; Li and Yang, 1974) and progesterone (McCormick and Moon, 1967; Jabara and Harcourt 1970) may also be important contributing hormonal factors in this neoplastic process.
In the male rat, mammary carcinomata are much more difficult to induce with hydrocarbon carcinogens, the yield being considerably less than that observed in the female rat (Dao and Greiner, 1961) . The hormones prerequisite for mammary carcinogenesis in the male rat are not known. The purpose of this study, therefore, is to determine whether or not marked changes in secretory activity of pituitary prolactin are influential in male mammary carcinogenesis as they most certainly are in the female rat. tered at a dose of 0-4 mg/100 g body weight and was prepared by dissolving the ergot in a minimal amount of 100% ethanol and diluting with 0-9% NaCl solution so that the final concentration was 2-0 mg CB-154/ml. The pituitary donor rats were of the same strain and age as the recipients, but ofopposite sex. All animals of Groups I and II received sham operations.
Twelve days after the beginning of treatments, all rats were given an initial single i.g. intubation of 7,12-dimethylbenzanthracene (DMBA) (10 mg/rat, dissolved in sesame oil) and at 2-week intervals thereafter for a total of 6 gastric intubations. After the last gastric intubation ofDMBA all animals were examined weekly for palpable mammary tumours. The mean latency period oftumour appearance was determined by calculating the average number of days from the initial day of carcinogen treatment to detection of each palpable tumour. Each mammary tumour, upon first detection, was excised, fixed in 10% formalin and stained with haematoxylin and eosin for histological evaluation.
All surviving rats were killed 35 weeks after the initial day of treatment. Blood was obtained from each rat and analysed by radioimmunoassay for prolactin. Differences between mean blood prolactin levels and between mean latency periods of mammary tumour appearance were evaluated statistically by Student's " t " test and tumour incidence was evaluated statistically by Chisquare analysis.
RESULTS
The results of this study are illustrated in the (Huggins and Sugiyama, 1966) . DISCUSSION The restults of this study show clearly that hydrocarbon induced mammary tumorigenesis in the male rat is markedly enhanced by concurrently increasing pituitary prolactin secretion. There were approximately 4 times more carcinomatous neoplasias and twice the number of sarcomatous outgrowths in the mammary glands of the hyperprolactinaemia group than in the control group. Although the total number of benign mammary tumours in the hyperprolactinaemia group was comparable with the control group, there was a striking shift in the histological characteristics of these tumours, i.e., nearly all the benign tumours in the control group were fibromatous whereas most of the benign tumours in the hyperprolactinaemia group had adenomatous microscopic features.
Unlike the female rat, hydrocarbon induced mammary tumorigenesis in the male rat has been rarely studied. Dao and associates (Dao and Sunderland, 1959; Dao and Greiner, 1961) showed that a series of pulse injections of 3-methylcholanthrene (MCA) to intact male rats failed to induce mammary tumours. However, if these rats were castrated a few tumours would develop and if the castrated rats were grafted with ovaries, tumour incidence in these male rats would rise markedly, nearly comparable with that observed in MCA treated female rats. These earlier studies clearly illustrated the inhibitory effects of androgens and the stimulatory effects of oestrogens in carcinogen induced male mammary tumorigenesis. The results of our study, using a more potent carcinogen, provide the first evidence that prolactin, in addition to oestrogen, is a stimulatory hormone in male mammary tumorigenesis in carcinogen treated rats. These results are in accord with the earlier report of Hagen and Rawlinson (1964) who showed that 8pontaneous mammary tumorigenesis in the male mouse can be increased by the grafting of multiple pituitaries to these animals.
Grafting of pituitaries to sites distant from the hypothalamus has long been a procedure recognized as an effective means to produce hyperprolactinaemia (Everett, 1954; Welsch, Negro-Vilar and Meites, 1968) . The grafts continuously secrete large amounts of prolactin and reduced amounts, if any, of all other pituitary hormones. In accord, approximately 3 times the level of prolactin was found in the serum ofthe grafted rats in this study when compared with the controls. More recently, it has been shown that the administration of a number of ergot alkaloids or ergoline derivatives can induce hypoprolactinaemia in rats Clemens et al., 1974) as well as in man (Lutterbeck et al., 1971) . CB-154 appears to be one of the most effective prolactin suppressors currently available (Brooks and Welsch, 1974) . Although the male rat normally secretes relatively small amounts of prolactin at least when compared with the female rat, chronic treatment of male rats with CB-154 in this study did significantly reduce the serum levels of this hormone in these animals.
It is interesting that such a reduction in serum prolactin levels did not significantly influence mammary tumorigenesis in these animals. This is quite uflike what is observed in the female rat Where an ergot alkaloid induced hypoprolactinaemia results in a striking reduction in both the development (Clemens and Shaar, 1972) and growth Stahelin, BurckhardtVisher and Fliuekiger, 1971) of DMBA induced mammary carcinomata. Furthermore, in female mice, the development of either spontaneous (Welsch and Gribler, 1973; Welsch, Gribler and Clemens, 1974) or induced (Yanai and Nagasawa, 1971) mammary carcinomata can be virtually prevented or sharply curtailed by an ergot alkaloid induced hypoprolactinaemia. It is probable that drug induced suppression of the secretion of this hormone in males does not result in a marked differential in the total quantity ofthe hormone secreted, because the male rat normally secretes relatively small amounts of prolactin.
Breast cancerigenesis in the human male is relatively uncommon (Hayward, 1970) . It has been hypothesized that the aetiology of this disease in males may be related to altered steroid metabolism leading to a heightened oestrogenicity (El-Gazayerli and Abdel-Aziz, 1963) . Indeed, the administration of oestrogens to male patients has been reported to result in an increase in breast cancer development (O'Grady and McDivitt, 1969) . Although prolactin has been implicated in cancerigenesis of the human female breast (Salih et al., 1972; Kwa et al., 1974) , it remains to be determined whether or not this hormone has a role in tumorigenesis of the human male breast. The results of this study provide convincing evidence that in the male rat treated with carcinogenic hydrocarbons, an elevation in the secretion of prolactin significantly increases mammary carcinogenesis.
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